>> Eurofins US News >> Eurofins Sponsors Chemistry Technology

Eurofins Sponsors Chemistry Technology exchange featuring 2016 Nobel Prize Winner in Chemistry – Dr. Bernard L. Feringa

Sidebar Image

Eurofins Sponsors Chemistry Technology exchange featuring 2016 Nobel Prize Winner in Chemistry – Dr. Bernard L. Feringa

Milwaukee, Wisconsin, USA – September 29, 2017

Eurofins SF Analytical (ESFA) sponsored a novel chemistry technology exchange organized by the University of Wisconsin Chemistry Department including a poster presentation and technology exchange involving 18 chemistry programs across the University of Wisconsin network. Dr. Bernard L. Feringa, 2016 Nobel Prize winner in Chemistry, gave the plenary speech and keynote address. Eurofin’s Dr. Michael Dziewatkoski introduced Dr. Feringa and five scientists from ESFA attended the exclusive event.

The University of Wisconsin Milwaukee (UW-MKE) chemistry program and ESFA enjoy a unique partnership which provides Eurofins scientists with exclusive and confidential access to state-of-the-art spectral analysis and structural elucidation equipment ranging from SEM-EDXA to NMR and chemical separation, quantitation and unique protein characterization capability. These technologies are all located in the newly commissioned 

Shimadzu Laboratory for Advanced and Applied Analytical Chemistry mass spectrometry facility located on UW-MKE campus just 20 minutes from ESFA in New Berlin, Wisconsin.Eurofins SFA with Nobel Winner Feringa

ESFA boasts five scientists who are UW-MKE graduates and three other scientists from University of Wisconsin affiliated chemistry programs. ESFA is the flagship investigative analytical lab for Eurofins North America and tackles the most challenging projects in food chemistry, specialty environmental, microbiology including foreign material identification, trace contamination in food, beverages and packaged products; chemical verification and ingredient/excipient release testing by USP, EP, JP, FCC, NF compendial methods, off-flavor/odor analysis, MICA fat claims, specialty environmental and elemental analysis as well as product recall support, insurance claim and litigation support for food, beverages, packaged products and specialty investigations across many sectors.

Eurofins was founded in 1987 by Gilles Martin in France with 10 people having a focus on food authenticity and quality. As Eurofins celebrates its 30th anniversary, the company has over 30,000 staff in more than 375 laboratories with over 130,000 methods across 41 countries. In the United States alone, there are 39 laboratories serving the needs of industry, research institutions, and academia.

Eurofins is a global network of laboratories specializing in chemical, bioanalytical, microbiological, and physical testing services for food, pharma, environmental, consumer products, and food safety training. The Eurofins Network offers solutions for both routine analysis and specialized testing and project management. The Eurofins path has been and continues to be fulfilling the mission: “To contribute to global health and safety by providing our customers with high-quality laboratory and advisory services…”

Notes for the editor:

Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.

With over 30,000 staff in more than 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.